Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
1. Goldman Sachs downgraded RGNX from Buy to Neutral due to uncertain gene therapy demand. 2. New anti-VEGF treatments are longer-lasting and cheaper, diminishing RGNX's outlook. 3. Phase 3 program planned for ABBV-RGX-314 in Diabetic Retinopathy is progressing. 4. Competing gene therapies are on the rise, impacting RGNX's market potential. 5. Recent strategic partnership may bolster RGNX's pipeline but faces tough competition.